Why Mungari, Joel? I just had a quick squiz at its webpage and Evolution has already kicked off expanding the mill there from 2mt pa to 4.2 mt pa which sort of suggests Evolution is more committed to expanding production at Mungari than Ramelius is at Mt Magnet. How long has Ramelius been dithering about increasing the capacity of its Checkers mill at Mt Magnet? (about as long as they've been dithering about getting a 3rd hub).
Is Evolution in the market for a discard from the New New merger?
As an aside, if Ramelius ends up buying Spartan for north of $800m their board needs to all give themselves a series of uppercuts. They had every opportunity to buy increased milling capacity in the Murchison by picking up a badly injured Spartan and its near new Dalgaranga mill for cents in the dollar 12-18 months back but they dithered. The fact that Never Never is turning out to be even better than Simon Lawson was claiming back then is just cream on top of what was already a logical transaction for Ramelius.
- Forums
- ASX - By Stock
- Ann: Record quarterly gold production for Ramelius
Why Mungari, Joel? I just had a quick squiz at its webpage and...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Is oil undervalued?
Add RMS (ASX) to my watchlist
|
|||||
Last
$1.91 |
Change
0.085(4.67%) |
Mkt cap ! $2.180B |
Open | High | Low | Value | Volume |
$1.90 | $1.91 | $1.87 | $4.797M | 2.533M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 311 | $1.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.91 | 77570 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 311 | 1.895 |
2 | 8319 | 1.890 |
8 | 43256 | 1.885 |
5 | 48905 | 1.880 |
4 | 36626 | 1.875 |
Price($) | Vol. | No. |
---|---|---|
1.910 | 77570 | 9 |
1.915 | 46185 | 2 |
1.920 | 39668 | 5 |
1.925 | 2695 | 1 |
1.930 | 2695 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
RMS (ASX) Chart |